NRX Pharmaceuticals Warrant
NRXPW
NRXPW was delisted on the 22nd of May, 2026.
2 hedge funds and large institutions have $4.29K invested in NRX Pharmaceuticals Warrant in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
16% more capital invested
Capital invested by funds: $3.69K → $4.29K (+$599)
0.01% less ownership
Funds ownership: 0.03% → 0.02% (-0.01%)
33% less funds holding
Funds holding: 3 → 2 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$604 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
YCM
1
Yakira Capital Management
Westport,
Connecticut
| $4.28K | – | – | – |
|
|
TRCT
2
Tower Research Capital (TRC)
New York
| $4 | – | – | – |
|
|
3
UBS Group
Zurich,
Switzerland
| – | -$604 | -3,356 | Closed |
|
NRXPW Hedge Fund Activity: Q2 2023 in Review
2 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals Warrant (NRXPW) for Q2 2023, worth a combined $4.29K — up 16% from $3.69K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of NRXPW and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was UBS Group, exiting entirely with an estimated $604 sold.
- 2 institutional investors held NRX Pharmaceuticals Warrant (NRXPW) as of Q2 2023, down from 3 in Q1 2023.
- Funds reported $4.29K of NRX Pharmaceuticals Warrant stock for Q2 2023, up 16% quarter-over-quarter.
- 0 funds opened new NRX Pharmaceuticals Warrant positions in Q2 2023 and 1 closed out, a net change of -1 holder.
- The largest NRX Pharmaceuticals Warrant seller in Q2 2023 was UBS Group, an estimated $604 sold.
Based on aggregated 13F filings for Q2 2023.